Form 4: GlycoMimetics Director Rachel K. King Acquires Shares in Lieu of Fees

Director Rachel K. King acquired 3,334 shares of GlycoMimetics stock on March 29, 2024, in lieu of $10,000 in board and committee retainer fees.

Summary

• On March 29, 2024, Rachel K. King, a director at GlycoMimetics Inc. (GLYC), acquired 3,334 shares of common stock.
• The acquisition was made in lieu of $10,000 in board and committee retainer fees, according to the issuer's non-employee director compensation policy.
• Following the transaction, Ms. King directly owns 515,194 shares.
• She also indirectly owns 7,500 shares through RBK LLC, 90,660 shares through various family trusts, and 45,741 shares through her spouse.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction related to director compensation. There is no indication of significant positive or negative implications for the company.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future.

Industry Context

This is a routine disclosure of insider transactions, which is common in the pharmaceutical industry.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it shows director alignment with company interests.

Key Dates